Seeking Alpha

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

NEW YORK, April 05, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, ...
Seeking Alpha

Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements

TORRANCE, Calif., June 26, 2025 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it has received Food and Drug Administration ...
MarketWatch

(PMZN) Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

The MarketWatch News Department was not involved in the creation of this content. STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a ...
Pharmabiz

Biotium launches GlycoLiner Cell Surface Glycoprotein Labelling Kits for rapid and selective cell surface imaging

Biotium launches GlycoLiner Cell Surface Glycoprotein Labelling Kits for rapid and selective cell surface imaging: Fremont, California Monday, January 5, 2026, 15:00 Hrs [IST] Bio ...
Morningstar

Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development, marketing, and sale of innovative treatments and therapies, including those for rare ...